Home infusions of natalizumab for relapsing-remitting MS are feasible, more convenient and less expensive than usual administration of the monoclonal antibody in the clinic, researchers say. A South Australian pilot study, randomised 37 adults on natalizumab for RRMS to home infusion delivered by nurses or usual clinic-based care for three infusions then crossed them over ...
Home infusions of natalizumab safe and feasible
By Mardi Chapman
22 Jul 2021